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Abstract 
Purpose: To isolate and characterize cancer stem-like side population (SP) cells from prostate cancer 
tissues using Hoechst 33342 dye exclusion. 
Methods: The presence of SP cells was analyzed in tumor samples by fluorescence activated cell 
sorting. The cell survival rate and ability for cell self-renewal using the sphere formation assay were 
evaluated after treatment with multiple drugs. 
Results: SP cells in the prostate cancer samples constituted 2.8 %, but fell to 0.6 % after treatment with 
verapamil. The SP cells showed high resistance to drugs such as 5-fluorouracil, cisplatin, paclitaxel (2 
μmol/L) and oxaliplatin. The survival rate of SP cells after treatment with these drugs was significantly 
higher (p < 0.01) than that of non-SP cells. Furthermore, the number of spheres generated in serum-
free medium was significantly higher in prostate cancer SP cells than in non-SP cells. 
Conclusion: The presence of SP cells is responsible for prostate treatment failure and tumor 
recurrence. Therefore, isolation and characterization of SP cells may provide new insights into the 
development of novel therapeutic agents targeting cancer stem cells for complete eradication of the 
tumor. 
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Prostate cancer is the most common cancer 
among males and one of the leading causes of 
death worldwide [1]. Treatment includes 
androgen deprivation therapy and chemotherapy 
based on the cancer stage after diagnosis. 
However, prostate cancer cells are highly drug-
resistant, which ultimately results in treatment 
failure and a high mortality rate. The major 
implications of drug resistance in tumor biology 
are often associated with chemotherapy failure, 
recurrence of the tumor and metastasis. 
  
Cancer stem cells (CSCs) have been identified 
as a small subset of cells within a tumor 
population. Several studies have demonstrated 
that the presence of CSCs is responsible for 
chemotherapy resistance and treatment failure. 
The biological characteristics of CSCs, such as 
self-renewal and a high proliferation rate, are 
similar to those of normal stem cells, which could 
have a detrimental effect on cancer treatment [2-
4]. Therefore, understanding the mechanism of 
CSCs in tumor relapse, as well as improved 
cancer treatments that specifically target and kill 
CSCs, are urgently needed in the current field of 
cancer treatment.  
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However, the isolation of such small CSC 
populations is challenging due to the lack of 
specific surface markers. The isolation and 
characterization of side population (SP) cells by 
Hoechst 33342 dye exclusion is useful in the 
characterization and targeting of CSCs. These 
SP cells share biological characteristics with 
CSCs, such as self-renewal, increased cell 
proliferation, multidrug resistance (MDR) and 
reduced apoptosis. In 1996, Goodell et al. [5] 
isolated hematopoietic stem cells from bone 
marrow by the Hoechst 33342 dye exclusion 
method. Subsequently, SP cells were identified 
in, and isolated from, several cancer types by 
Hoechst 33342 dye exclusion using fluorescence 
activated cell sorting (FACS) [6].  
 
Similar to several other cancers, the presence of 
CSCs in prostate cancer may be the root cause 
of treatment failure, cancer metastasis and tumor 
recurrence. Prostate CSCs undergo abnormal 
differentiation and form heterogeneous tumor 
cells with high tumorigenicity and unregulated 
cell proliferation. In addition, CSCs express stem 
cell surface markers, such as CD44, CD133, 
CD147 and ALDH1, and elevated expression of 
adenosine triphosphate binding cassette (ABC) 
transporters [7] and anti-apoptotic factors, which 
contribute to self-renewal, MDR and reduced 
apoptosis [8,9]. Therefore, characterization and 
understanding of the biological functions of 
prostate CSCs might provide further insight into 
the mechanism of drug resistance and help 
identify useful therapeutic targets to improve the 
current therapeutic modalities.  
 
Consequently, the aims of the present work were 
to isolate CSCs from prostate cancer based on 
Hoechst 33342 dye exclusion and to identify 
novel therapeutic agents targeting CSCs for 




Sample collection and cell culture 
 
Primary prostate cancer tissues were collected 
from 10 patients with lymph node metastases at 
the time of surgery (radical prostatectomy) 
following ethical approval from Southern Medical 
University, Guangzhou, Guangdong, China. The 
cancer tissues were washed extensively in PBS 
containing antibiotics and incubated overnight in 
DMEM/F12 (Gibco) containing penicillin (500 
U/mL), streptomycin (500 μg/mL) and 
amphotericin B (1.25 μg/mL) (Gibco) at 37 ºC. 
Enzymatic digestion was performed using 
collagenase (1.5 mg/mL) (Gibco) and 
hyaluronidase (20 μg/mL) in PBS for 1 h. Cells 
were cultured in DMEM supplemented with 10 % 
FBS and antibiotics and maintained in T75 flasks 
at 37 ºC in a humidified 5 % CO2 and 95 % air 
atmosphere. Upon reaching 90 % confluency, 
the cells were removed from the culture flask 
using trypsin (0.25 %)-EDTA (53 mM), washed 
and suspended in 10 % DMEM. The cells were 
counted using a hemocytometer. The study was 
approved by Medical Ethics Committee of the 
People’s Hospital of Zoucheng (approval ref no. 
ZC2010091) and followed the guidelines of 
Council for International Organizations of Medical 
Sciences (CIOMS) [10]. 
 
Labeling with Hoechst 33342 dye 
 
The study groups included control cells labeled 
with Hoechst 33342 dye alone (n = 3) and 
treatment cells labeled with Hoechst 33342 dye 
and treated with verapamil (n = 5). The Hoechst 
33342 dye labeling protocol was obtained from 
Dr. Wanshan Li, Department of Oral and 
Maxillofacial Surgery, Chongqing Medical 
University by personal communication.  
 
Cells were counted using a hemocytometer, and 
approximately 106 cells/mL in 10 % DMEM were 
labeled with bisbenzimide Hoechst 33342 stock 
solution (5 μL/mL; Sigma), either alone or in 
combination with verapamil (0.8 μL/mL). Cells 
were then counterstained with 2 μg/mL 
propidium iodide. The cells were sorted using a 
flow cytometer, and the sorted cells were 
cultured and maintained in DMEM/F-12 
supplemented with 10 % FBS. The Hoechst 
33342 dye was excited at 355 nm, and its dual 
wavelength fluorescence was analyzed (blue, 




The immunostaining of spheroids was performed 
as described previously [11]. Spheroids were 
fixed onto glass slides using ice-cold 4 % 
paraformaldehyde (4 oC, 10 min), blocked with 
normal serum for 30 min and incubated with 
mouse monoclonal anti-Oct4 (1:200; Chemicon, 
Japan) overnight. After washing the slides with 
PBS, they were incubated with FITC-conjugated 
chicken anti-rat IgG overnight in a dark room. 
Nuclei were counterstained with Hoechst 33342 
dye and viewed by fluorescence microscopy, and 
the resulting images were processed using 
Image J software (ver. 1.4; NIH). 
 
Drug resistance assay 
 
The cells were assayed for drug resistance as 
described previously [5]. Approximately 1 × 103 
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cells/plate were cultured in 96-well plates and 
treated with 5-fluorouracil (5-FU) (10 μg/mL), 
cisplatin (20 μmol/L), paclitaxel (2 μmol/L) and 
oxaliplatin (100 mM). The absorbance at 450 nm 
was obtained spectrophotometrically. Cell 
resistance to the drugs was calculated for both 
groups using Eq 1 [12].  
 
Cell resistance (%) = (Ae/Ac) 100 …………. (1) 
 
where Ae and Ac are the absorbances of the 
experimental and control groups, respectively.  
 
Sphere formation assay 
 
The sphere formation assay was performed 
exactly as described previously. The sorted SP 
and non-SP cells were resuspended at a density 
of 1,000/mL in serum-free tumor sphere medium 
consisting of Ham’s F-12/DMEM (1:1), 10 ng/mL 
human recombinant bFGF and 10 ng/mL EGF 
and were subsequently cultured in ultra-low 
attachment plates for approximately 2 weeks. 
The sorted SP and non-SP cells were seeded at 
a low density of 20/L, and the number of spheres 




One-way analysis of variance (ANOVA) and 
Student’s t-test were performed to determine 
significant differences between the treatment and 
control groups. P < 0.05 was considered 
statistically significant. Statistical analysis was 
performed using GraphPad Prism software (ver. 




Side population cells  
 
As shown in the dot plot generated from the 
FACS data (Figure 1), the proportion of SP cells 
observed was approximately 2.8 %. The number 
of cells identified was approximately 59,000, 
which was approximately 55 % of the initial cell 
count. Of the 59,000 cells (P1) analyzed, 2.8 % 
showed Hoechst dye efflux in the P2 gated 
region of the dot plot (Figure 1) Treatment with 
verapamil, an inhibitor of the MDR1 transporter, 
resulted in a reduced proportion (0.6 %) of SP 
cells (Figure 2). 
 
 
Figure 1: Representative dot plot analysis by fluorescence activated cell sorting (FACS) showing the presence of 
2.8 % side population (SP) cells in prostate cancer samples in the P2 gated region 
 
Wang et al 
Trop J Pharm Res, November 2016; 15(11): 2360  
 
 
Figure 2: Representative dot plot analysis by FACS showing the reduction of SP cells (0.6 %) after treatment 




Figure 3: (A) Quantification of the number of spheres generated by the sorted SP and non-SP cells, which were 
counted after 7 days of culturing. The SP cells produced significantly more tumor spheres than did non-SP cells. 
(B) Comparison of cell survival rates between SP and non-SP cells after treatment with 5-fluorouracil, cisplatin, 
paclitaxel and oxaliplatin 
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Figure 4: Representative immunostaining of Oct4 in tumor spheres generated by prostate cancer SP cells. (A) 
Bright field micrographs of the sphere cells. (B) Fluorescent Hoechst 33342 staining (blue) of the nucleus. (C) 
Immunostaining of anti-Oct4 (green fluorescence). (D) Overlay of the images from (B) and (C) 
 
Characteristics of SP cells derived from 
prostate cancer 
 
After carefully analyzing the presence of SP cells 
by FACS, the SP and non-SP cells were sorted 
separately by FACS. To examine the 
chemoresistant phenotype and self-renewing 
capacity of the CSCs, the sorted SP and non-SP 
cells were subjected to drug resistance and 
sphere formation assays. The SP cells showed 
high resistance to drugs such as 5-FU, cisplatin, 
paclitaxel (2 μmol/L) and oxaliplatin. The survival 
rate of SP cells after treatment with these drugs 
was significantly higher (p < 0.01) than that of 
non-SP cells (Figure 3A). Furthermore, the 
number of spheres generated in serum-free 
medium was significantly higher in prostate 
cancer SP cells than in non-SP cells (Figure 3B). 
We also found that the spheres formed by SP 
cells were Oct4-positive by immunofluorescence 
(Figure 4A–D). From these data, it is clear that 





CSCs identified in several cancers appear to 
resist DNA-damaging agents due to high 
expression of efflux pumps and enhanced DNA 
repair capacity. These properties may explain the 
long-term treatment failure of standard 
chemotherapies, which initially result in tumor 
shrinkage by killing most neoplastic cells; 
however, the cancer eventually relapses due to 
the robust nature and resistance of CSCs [1-5]. 
Most traditional treatments have the ability to kill 
the majority of the tumor population, with the 
exception of CSCs, which are highly resistant to 
chemotherapy. These resistant CSCs are 
responsible for tumor growth, metastasis and 
relapse. Hence, the elimination of CSCs is an 
important goal in eradicating refractory cancers 
and providing long-term disease-free survival.  
 
One of the characteristic features of CSCs used 
for their identification is their capacity to extrude 
dyes such as Hoechst 33342. Cells that exclude 
this dye are referred to as SP cells [6]. These 
cells share characteristics with CSCs; 
specifically, both cell types exhibit a capacity for 
tumor initiation, expression of stem-like genes, 
and resistance to chemotherapeutic drugs. Dye 
exclusion is a valuable technique, as it identifies 
a unique population of cells with stem-like 
characteristics. 
 
According to recent findings, SP cells are present 
in various types of cancer, including cancers of 
the blood, liver, lung, skin, nasopharyngeal, 
ovary and central nervous system [13-17]. SP 
cells share fundamental and similar biological 
characteristics with CSCs, such as differentiation 
potential, deregulation of the cell cycle, high 
tumorigenic ability and resistance to 
chemotherapeutic drugs. However, the use of 
various markers for isolating SP cells has been 
strongly debated. In the current study, we used 
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the Hoechst 33342 dye exclusion technique for 
identification and isolation of SP cells from 
prostate cancer. Similar to other tumors, SP cells 
are present in prostate tumors.  
 
We identified SP cells in our prostate cancer 
samples at a prevalence of 2.8 %, which was 
reduced to 0.6 % after treatment with verapamil. 
Therefore, Hoechst 33342 dye exclusion can be 
used to isolate SP cells. The exclusion of 
Hoechst 33342 dye from SP cells is most likely 
the result of overexpression of MDR transporters, 
such as ABCB1 and ABCG2, which might be 
responsible for drug resistance and treatment 
failure. The sorted SP cells were highly resistant 
to various drugs including 5-FU, cisplatin, 
oxaliplatin and paclitaxel, and the survival rate of 
SP cells after treatment with these drugs was 
significantly higher compared with that of non-SP 
cells. This increased survival rate could be 
explained by two different mechanisms: i) 
activation and overexpression of ABC 
transporters (e.g., ABCB1 and ABCG2), which 
expel harmful mate¬rials from cells, and ii) 
elevated expression of anti-apoptotic factor bcl-2, 
which ultimately results in reduced apoptosis 
[18]. Similar to previous findings in gastric cancer 
cell lines, we speculate that both processes 
occur in SP cells.   
 
The most important feature of CSCs is their 
strong ability to form tumor spheres, which can 
also be used as a marker to isolate CSCs. We 
clearly showed that isolated SP cells form tumor 
spheres positive for Oct4 immunostaining. Oct4 
expression suggests that SP cells have a high 
capacity for self-renewal. These SP cells are 
hypothesized to exhibit increased expression of 
stem cell surface markers, such as CD44/CD147 
and bcl-2, which confer significant prostate 
cancer metastasis, self-renewal and apoptotic 
resistance capabilities, respectively. These 
research questions have yet to be answered. 
Therefore, characterization of SP cells enables 
the design of novel therapeutic agents that 
selectively target CSCs and improve cancer 
therapy by blocking ABC transporters. 
Furthermore, the differences in signaling 
pathways between normal cells and CSCs need 
to be elucidated before novel therapeutic targets 
with the eventual goal of eliminating residual 




The presence of SP cells is responsible for 
prostate cancer treatment failure and tumor 
recurrence. Therefore, isolation and 
characterization of SP cells may provide new 
insights into the development of novel 
therapeutic agents targeting CSCs for complete 
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